Last reviewed · How we verify
Licensed DTaP
At a glance
| Generic name | Licensed DTaP |
|---|---|
| Sponsor | BioNet-Asia Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers (PHASE2, PHASE3)
- Hepatitis B Vaccination in Infants (PHASE4)
- Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines (PHASE3)
- Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children (PHASE2)
- Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine
- Pentavalent DTaP-Hep B-IPV (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Licensed DTaP CI brief — competitive landscape report
- Licensed DTaP updates RSS · CI watch RSS
- BioNet-Asia Co., Ltd. portfolio CI